|
Gene: FOSL2 |
Gene summary for FOSL2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | FOSL2 | Gene ID | 2355 |
Gene name | FOS like 2, AP-1 transcription factor subunit | |
Gene Alias | FRA2 | |
Cytomap | 2p23.2 | |
Gene Type | protein-coding | GO ID | GO:0002064 | UniProtAcc | P15408 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2355 | FOSL2 | LZE2D | Human | Esophagus | HGIN | 1.95e-04 | -1.12e-01 | 0.0642 |
2355 | FOSL2 | LZE4T | Human | Esophagus | ESCC | 1.58e-12 | 1.60e-02 | 0.0811 |
2355 | FOSL2 | LZE7T | Human | Esophagus | ESCC | 1.38e-06 | 3.43e-01 | 0.0667 |
2355 | FOSL2 | LZE8T | Human | Esophagus | ESCC | 2.11e-13 | -1.97e-02 | 0.067 |
2355 | FOSL2 | LZE20T | Human | Esophagus | ESCC | 5.69e-04 | 9.02e-03 | 0.0662 |
2355 | FOSL2 | LZE21D1 | Human | Esophagus | HGIN | 4.59e-03 | -2.28e-01 | 0.0632 |
2355 | FOSL2 | LZE22D1 | Human | Esophagus | HGIN | 2.08e-02 | -1.82e-01 | 0.0595 |
2355 | FOSL2 | LZE24T | Human | Esophagus | ESCC | 1.21e-09 | 5.82e-01 | 0.0596 |
2355 | FOSL2 | LZE21T | Human | Esophagus | ESCC | 6.64e-04 | 2.35e-01 | 0.0655 |
2355 | FOSL2 | LZE6T | Human | Esophagus | ESCC | 9.01e-08 | -2.62e-02 | 0.0845 |
2355 | FOSL2 | P2T-E | Human | Esophagus | ESCC | 7.94e-09 | 1.71e-01 | 0.1177 |
2355 | FOSL2 | P4T-E | Human | Esophagus | ESCC | 1.56e-07 | 3.80e-01 | 0.1323 |
2355 | FOSL2 | P5T-E | Human | Esophagus | ESCC | 1.61e-16 | 1.81e-01 | 0.1327 |
2355 | FOSL2 | P8T-E | Human | Esophagus | ESCC | 3.07e-04 | 4.13e-02 | 0.0889 |
2355 | FOSL2 | P9T-E | Human | Esophagus | ESCC | 3.18e-13 | 3.22e-01 | 0.1131 |
2355 | FOSL2 | P10T-E | Human | Esophagus | ESCC | 7.07e-11 | 2.87e-01 | 0.116 |
2355 | FOSL2 | P11T-E | Human | Esophagus | ESCC | 1.12e-03 | 6.09e-01 | 0.1426 |
2355 | FOSL2 | P12T-E | Human | Esophagus | ESCC | 3.71e-11 | 4.16e-01 | 0.1122 |
2355 | FOSL2 | P15T-E | Human | Esophagus | ESCC | 3.79e-13 | 5.44e-01 | 0.1149 |
2355 | FOSL2 | P16T-E | Human | Esophagus | ESCC | 8.00e-13 | -1.37e-01 | 0.1153 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004814422 | Skin | cSCC | fibroblast proliferation | 38/4864 | 81/18723 | 3.88e-05 | 4.17e-04 | 38 |
GO:000206426 | Skin | cSCC | epithelial cell development | 84/4864 | 220/18723 | 4.33e-05 | 4.56e-04 | 84 |
GO:000991324 | Skin | cSCC | epidermal cell differentiation | 78/4864 | 202/18723 | 5.12e-05 | 5.28e-04 | 78 |
GO:004814522 | Skin | cSCC | regulation of fibroblast proliferation | 37/4864 | 80/18723 | 7.15e-05 | 6.87e-04 | 37 |
GO:00033342 | Skin | cSCC | keratinocyte development | 8/4864 | 13/18723 | 7.25e-03 | 3.44e-02 | 8 |
GO:000206427 | Thyroid | HT | epithelial cell development | 35/1272 | 220/18723 | 2.12e-06 | 7.61e-05 | 35 |
GO:004814510 | Thyroid | HT | regulation of fibroblast proliferation | 16/1272 | 80/18723 | 8.03e-05 | 1.40e-03 | 16 |
GO:00481449 | Thyroid | HT | fibroblast proliferation | 16/1272 | 81/18723 | 9.39e-05 | 1.58e-03 | 16 |
GO:00481466 | Thyroid | HT | positive regulation of fibroblast proliferation | 11/1272 | 48/18723 | 2.98e-04 | 4.01e-03 | 11 |
GO:0002064112 | Thyroid | PTC | epithelial cell development | 101/5968 | 220/18723 | 8.53e-06 | 9.74e-05 | 101 |
GO:004814516 | Thyroid | PTC | regulation of fibroblast proliferation | 41/5968 | 80/18723 | 2.43e-04 | 1.75e-03 | 41 |
GO:004814416 | Thyroid | PTC | fibroblast proliferation | 41/5968 | 81/18723 | 3.41e-04 | 2.35e-03 | 41 |
GO:004814612 | Thyroid | PTC | positive regulation of fibroblast proliferation | 24/5968 | 48/18723 | 6.73e-03 | 2.90e-02 | 24 |
GO:004814532 | Thyroid | ATC | regulation of fibroblast proliferation | 49/6293 | 80/18723 | 3.73e-07 | 5.48e-06 | 49 |
GO:004814432 | Thyroid | ATC | fibroblast proliferation | 49/6293 | 81/18723 | 6.38e-07 | 8.80e-06 | 49 |
GO:004814621 | Thyroid | ATC | positive regulation of fibroblast proliferation | 31/6293 | 48/18723 | 1.11e-05 | 1.08e-04 | 31 |
GO:000206428 | Thyroid | ATC | epithelial cell development | 103/6293 | 220/18723 | 3.06e-05 | 2.55e-04 | 103 |
Page: 1 2 3 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa043806 | Oral cavity | OSCC | Osteoclast differentiation | 73/3704 | 128/8465 | 1.60e-03 | 4.44e-03 | 2.26e-03 | 73 |
hsa0438011 | Oral cavity | OSCC | Osteoclast differentiation | 73/3704 | 128/8465 | 1.60e-03 | 4.44e-03 | 2.26e-03 | 73 |
hsa043802 | Oral cavity | EOLP | Osteoclast differentiation | 44/1218 | 128/8465 | 8.92e-09 | 1.37e-07 | 8.10e-08 | 44 |
hsa043803 | Oral cavity | EOLP | Osteoclast differentiation | 44/1218 | 128/8465 | 8.92e-09 | 1.37e-07 | 8.10e-08 | 44 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FOSL2 | SNV | Missense_Mutation | novel | c.128C>T | p.Ser43Leu | p.S43L | P15408 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
FOSL2 | SNV | Missense_Mutation | c.439N>C | p.Glu147Gln | p.E147Q | P15408 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-E2-A15L-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
FOSL2 | insertion | Frame_Shift_Ins | novel | c.911_912insGCAATCT | p.His304GlnfsTer8 | p.H304Qfs*8 | P15408 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
FOSL2 | SNV | Missense_Mutation | novel | c.534G>T | p.Glu178Asp | p.E178D | P15408 | protein_coding | tolerated(0.16) | benign(0.018) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FOSL2 | SNV | Missense_Mutation | c.58N>G | p.Pro20Ala | p.P20A | P15408 | protein_coding | deleterious(0.01) | possibly_damaging(0.757) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
FOSL2 | SNV | Missense_Mutation | rs143327177 | c.596N>A | p.Arg199Gln | p.R199Q | P15408 | protein_coding | tolerated(0.65) | benign(0.003) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
FOSL2 | SNV | Missense_Mutation | rs199613963 | c.248N>T | p.Ser83Ile | p.S83I | P15408 | protein_coding | deleterious(0.03) | possibly_damaging(0.758) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
FOSL2 | SNV | Missense_Mutation | novel | c.908N>T | p.Ala303Val | p.A303V | P15408 | protein_coding | tolerated(0.06) | probably_damaging(0.986) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
FOSL2 | SNV | Missense_Mutation | novel | c.331N>T | p.Gly111Cys | p.G111C | P15408 | protein_coding | deleterious(0.01) | probably_damaging(0.927) | TCGA-AJ-A3OJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
FOSL2 | SNV | Missense_Mutation | c.383G>A | p.Arg128His | p.R128H | P15408 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |